|
|
|
|
| LEADER |
01718nam a2200265 u 4500 |
| 001 |
EB002191849 |
| 003 |
EBX01000000000000001329314 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.)
|h Elektronische Ressource
|b indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
|
| 246 |
3 |
1 |
|a Clinical review report for Brolucizumab (Beovu)
|
| 246 |
3 |
1 |
|a Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.)
|
| 250 |
|
|
|a Version: Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, July 2020
|
| 300 |
|
|
|a 1 PDF file (88 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565330
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a The objective of this review is to perform a systematic review of the beneficial and harmful effects of brolucizumab for the treatment of neovascular age-related macular degeneration. The systematic review protocol for the current review was established prior to the anticipated issuance of the Health Canada Notice of Compliance for brolucizumab, expected on March 12, 2020. The expected recommended dose for brolucizumab is 6 mg (50 μL) administered by intravitreal (IVT) injection every four weeks for the first three doses and every 12 weeks thereafter
|